-
Posted by
Two Blokes Jun 19 -
Filed in
Stock
-
2 views
Revolution Medicines is advancing a groundbreaking pan-RAS inhibitor pipeline, targeting historically undruggable mutations in tough cancers like pancreatic and lung. Early clinical data for daraxonrasib and zoldonrasib show strong efficacy and tolerability, sparking excitement among oncologists and analysts alike. Despite a robust cash position, RVMD's high burn rate and lofty valuation increase risk and sensitivity to setbacks, making entry timing challenging.
